Table 2.
Existing reports of ANCA-associated vasculitis after SARS-CoV-2 vaccination, anti-GBM disease, or double-positive [10–27]
| No | Author | Sex | Age | Complications | Diagnosis | Days | Vaccine type | Vaccine doses | Anti-GBM | ANCA |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tan | F | 60 | IgAN | Anti-GBM | 1 | Pfizer | 2 | Y | N |
| 2 | Sacker | F | N/A | None | Anti-GBM | 14 | Moderna | 2 | Y | N |
| 3 | Nagai | F | 70 | None | Anti-GBM | 9 | N/A | 2 | Y | N |
| 4 | Shakoor | F | 78 | DM, HTN, Af | AAV | 6 | Pfizer | 2 | N | Y |
| 5 | Dube | F | 29 | Cystic lung disease | AAV | 16 | Pfizer | 2 | N | Y |
| 6 | Sekar | M | 52 | HTN | AAV | 14 | Moderna | 2 | N | Y |
| 7 | Andergg | M | 81 | N/A | AAV | 22 | Moderna | 2 | N | Y |
| 8 | Baier | F | 57 | None | AAV | 5 | Pfizer | 2 | N | Y |
| 9 | Okuda | F | 37 | Graves’ disease | AAV | 12 | Pfizer | 1 | N | Y |
| 10 | Hakroush | F | 79 | HTN, degenerative disk disease | AAV | 14 | Pfizer | 2 | N | Y |
| 11 | Villa M | M | 63 | N/A | AAV | 7 | AstraZeneca | 1 | N | Y |
| 12 | Feghali | M | 58 | N/A | AAV | 4 | Moderna | 2 | N | Y |
| 13 | Felzer | F | 60 | N/A | AAV | 1 | Moderna | 1 | N | Y |
| 14 | Garcia | F | 78 | Odontogenic maxillary sinusitis | AAV | 14 | Sinovac | 1 | N | Y |
| 15 | Ibrahim | F | 79 | Asthma, gastroesophageal reflux disease | AAV | 7 | Moderna | 2 | N | Y |
| 16 | Prabhahar | M | 51 | N/A | AAV | 15 | AstraZeneca | 1 | N | Y |
| 17 | Prema | M | 45 | N/A | AAV | 12 | Bharat | 1 | N | Y |
| 18 | Gupta | M | 23 | Fragile X syndrome, interstitial lung disease | AAV | 14 | Moderna | 2 | Y | Y |
| 19 | Prema | M | 58 | N/A | AAV | 14 | Bharat | 2 | Y | Y |